A phase I study of intermediate dose cytarabine in combination with lenalidomide in relapsed/refractory acute myeloid leukemia.

Autor: Griffiths EA; Department of Medicine, Roswell Park Cancer Institute, Elm & Carlton Sts, Buffalo, NY 14263, United States. Electronic address: elizabeth.griffiths@roswellpark.org., Brady WE; Department of Biostatistics & Bioinformatics, Roswell Park Cancer Institute, Elm & Carlton Sts, Buffalo, NY 14263, United States., Tan W; Department of Biostatistics & Bioinformatics, Roswell Park Cancer Institute, Elm & Carlton Sts, Buffalo, NY 14263, United States., Vigil CE; Department of Medicine, Roswell Park Cancer Institute, Elm & Carlton Sts, Buffalo, NY 14263, United States., Thompson JE; Department of Medicine, Roswell Park Cancer Institute, Elm & Carlton Sts, Buffalo, NY 14263, United States., Ford LA; Department of Medicine, Roswell Park Cancer Institute, Elm & Carlton Sts, Buffalo, NY 14263, United States; Clinical Research Services, Roswell Park Cancer Institute, Elm & Carlton Sts, Buffalo, NY 14263, United States., Dickey NM; Department of Medicine, Roswell Park Cancer Institute, Elm & Carlton Sts, Buffalo, NY 14263, United States; Clinical Research Services, Roswell Park Cancer Institute, Elm & Carlton Sts, Buffalo, NY 14263, United States., L Bashaw H; Department of Medicine, Roswell Park Cancer Institute, Elm & Carlton Sts, Buffalo, NY 14263, United States; Clinical Research Services, Roswell Park Cancer Institute, Elm & Carlton Sts, Buffalo, NY 14263, United States., Sperrazza J; Department of Medicine, Roswell Park Cancer Institute, Elm & Carlton Sts, Buffalo, NY 14263, United States., Wetzler M; Department of Medicine, Roswell Park Cancer Institute, Elm & Carlton Sts, Buffalo, NY 14263, United States., Wang ES; Department of Medicine, Roswell Park Cancer Institute, Elm & Carlton Sts, Buffalo, NY 14263, United States.

Publikováno v: Leukemia research [Leuk Res] 2016 Apr; Vol. 43, pp. 44-8. Date of Electronic Publication: 2016 Feb 16.